JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 106 filers reported holding JOUNCE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 1.23 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $27,121 | -67.3% | 14,660 | -58.8% | 0.00% | – |
| Q3 2022 | $83,000 | +22.1% | 35,599 | +58.2% | 0.00% | – |
| Q2 2022 | $68,000 | -59.0% | 22,500 | -8.2% | 0.00% | -100.0% |
| Q1 2022 | $166,000 | -19.0% | 24,500 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $205,000 | +12.6% | 24,500 | 0.0% | 0.00% | -50.0% |
| Q3 2021 | $182,000 | +9.0% | 24,500 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $167,000 | -24.4% | 24,500 | +14.0% | 0.00% | 0.0% |
| Q1 2021 | $221,000 | +176.2% | 21,500 | +87.0% | 0.00% | +100.0% |
| Q4 2020 | $80,000 | -19.2% | 11,500 | +4.5% | 0.00% | -50.0% |
| Q3 2020 | $99,000 | +35.6% | 11,000 | 0.0% | 0.00% | +100.0% |
| Q2 2020 | $73,000 | – | 11,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP II, LLC | 572,829 | $1,340,000 | 100.00% |
| TRV GP III, LLC | 1,148,780 | $2,688,000 | 1.17% |
| COWEN AND COMPANY, LLC | 3,647,430 | $8,535,000 | 0.82% |
| Octagon Capital Advisors LP | 1,400,000 | $3,276,000 | 0.56% |
| Deep Track Capital, LP | 4,259,653 | $9,968,000 | 0.46% |
| PFM Health Sciences, LP | 4,094,488 | $9,581,000 | 0.35% |
| RTW INVESTMENTS, LP | 5,106,341 | $11,949,000 | 0.28% |
| Omega Fund Management, LLC | 275,513 | $645,000 | 0.24% |
| Monarch Partners Asset Management LLC | 228,370 | $534,000 | 0.16% |
| Orbimed Advisors | 2,928,900 | $6,854,000 | 0.13% |